Prolotherapy for Osteoarthritis


Dr. Deirdre O’Neill

Some of us can predict the weather without looking at the barometer. It’s when the joints start talking – cracking, achy, and stiff – as the weather turns to the damp wet coast that we all know well.

These joint symptoms are the signature of arthritis. This inflammatory condition of the joints can bring with it cartilage deterioration. But more importantly to the person affected – pain and subsequent reduction in activity.

Out come the medications. The caution with the long term use of NSAIDS is that it accelerates the breakdown of cartilage in osteoarthritis1. This treatment gives a patient temporary pain relief, yet it increases the likelihood of degeneration in the joint. Instead of reaching for NSAIDS to stop the pain, treat the cause of arthritis.

Remember that joint pain is a result of wear and tear. Osteoarthritis is more common in joints with a history of injury. The treatment modalities of prolotherapy and platelet rich plasma fall under the umbrella of regenerative injection therapies. The treatments are geared toward promoting tissue repair and subsequently reducing pain.

Research has shown that prolotherapy is an effective treatment for osteoarthritis. One study on knee osteoarthritis showed that MRI and pain severity were improved at a year2.

This fall change how you can determine the weather by learning more about how regenerative injection therapy can benefit you. An appointment with Dr. Deirdre O’Neill will cover an orthopedic exam pertaining to your pain, and a review of the ins and outs of prolotherapy and platelet rich plasma therapy.


  1. Hauser R. The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-inflammatory Drugs. Journal of Prolotherapy 2010 Feb:2(1) 305-22.
  2. Rabago D, Zgierska A, Fortney L, Kijowski R, Mundt M, Ryan M, Grettie J, Patterson JJ.Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: results of a single-arm uncontrolled study with 1-year follow-up. J Altern Complement Med. 2012 Apr;18(4):408-14.